Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archived Events
Date Event Details
May 7, 2014
4:30 PM ET
First Quarter 2014 Update

Participant Dial-In Toll-free Number:  (855) 232-3919
Participant Dial-In Toll Number:  (315) 625-6894

Apr 11, 2014
OCA Highlighted in 1st EASL 2014 Press Conference
Speaker: Professor Markus Peck-Radosavljevic
Apr 8–12, 2014
OCA Presentations and Relevant Symposia at EASL April 2014

A schedule highlighting key OCA presentations and relevant symposia at and around EASL 2014 follows:

Oral Presentations

  • “Obeticholic Acid, A Farnesoid-X Receptor Agonist, Reduces Bacterial Translocation and Restores Intestinal Permeability In A Rat Model Of Cholestatic Liver Disease” – Thursday, April 10 at 14:15 in the ICC Auditorium during the General Session I & Opening.  
    Len Verbeke, MD, Department of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium

  • “The First Primary Biliary Cirrhosis (PBC) Phase 3 Trial in Two Decades – an International Study of the FXR Agonist Obeticholic Acid in PBC Patients” – Saturday, April 12 at 16:45 in the ICC Auditorium during the Late Breaker Session.  Frederick Nevens, MD, Department of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium

This late breaker presentation will provide new data from the Phase 3 POISE clinical trial. Top-line results, announced on March 16, 2014, showed that OCA met the study’s primary endpoint and produced clinically meaningful improvements across a broad range of biochemical liver function parameters.

Poster Presentations

  • “Long-Term Treatment of Primary Biliary Cirrhosis with the FXR Agonist Obeticholic Acid Shows Durable Efficacy” – Thursday, April 10, from the Autoimmune and Chronic Cholestatic Liver Disease section.  Kris Kowdley, MD, Department of Gastroenterology and Hepatology, Virginia Mason Medical Center
  • “The FXR Agonist Obeticholic Acid Improves a Transplant-Free Survival-Proven Biochemical Response Criterion In Placebo Controlled Primary Biliary Cirrhosis Studies” – Thursday, April 10, from 9:00 – 16:00 in the Autoimmune and Chronic Cholestatic Liver Disease section.  Velimir Luketic, MD, Department of Gastroenterology, Virginia Commonwealth University Medical Center



  • “PBC: Past, Present and Future” Hosted by UK-PBC Consortium at the Royal College of Physicians of London. April 8, 13:00 – 17:30. Program includes, Alan Hofmann, MD, Professor Emeritus University of California San Diego, USA, David E. J. Jones, Newcastle University, USA, Dean of Research and Innovation, Keith Lindor MD, Executive Vice Provost and Dean,  Arizona State University, USA, Henk van Buuren, MD PhD, Erasmus Medical Center, The Netherlands, Gideon Hirschfield MD, Senior Lecturer , Univesity of Birmingham, UK.  Admission free, if registered:


  • “Changing Dynamics in the Science and Clinical Management of Primary Biliary Cirrhosis: What They Mean for Us, What They Mean for Our Patients” – Saturday, April 12, at 18:00 in the Capital Suite 2-3-4.

Program includes: David E.J. Jones, MD, PhD Dean of Research and Innovation Newcastle University Newcastle upon Tyne, United Kingdom; Ulrich H.W. Beuers, MD Professor Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal Research University of Amsterdam Amsterdam, The Netherlands

For more information and to register, please visit Registration is free.This symposium is supported by an educational grant from Intercept Pharmaceuticals

= add file to Briefcase